✨ Free AI Report
Cardiff Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cardiff Oncology, Inc.
Company Research

Cardiff Oncology, Inc.: Business Overview, Financials & Competitive Analysis

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's lead asset, onvansertib, is in late-stage development for first-line RAS-mutated m...

Analyst-debate audio for Cardiff Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for Cardiff Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

PLK1 inhibition in first-line mCRC represents practice-changing potential with unmet medical need, supported by positive Phase 2...

Read the full analyst-debate transcript →
Industry Oncology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cardiff Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cardiff Oncology, Inc. Overview

Pro stress-test →

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's lead asset, onvansertib, is in late-stage development for first-line RAS-mutated metastatic colorectal cancer (mCRC), a large underserved patient population with significant unmet medical need.

Strategic Profile

Pro stress-test →

Cardiff presented positive Phase 2 data at ASCO in June 2026, with the selected 30 mg onvansertib plus FOLFIRI/bevacizumab regimen demonstrating deep and durable tumor shrinkage with clinically meaningful improvements in confirmed ORR and PFS compared to standard of care alone, with no additive adverse events. The company completed a $10 million registered direct offering in August 2026 and plans to initiate a planned registrational trial in Q1 2027, subject to securing additional financing.

Competitive Landscape

Pro stress-test →

Cardiff operates in the oncology drug development space, competing with other companies developing colorectal cancer therapeutics. The competitive landscape includes established players developing novel approaches to RAS-mutated mCRC, though PLK1 inhibition represents a distinct mechanism of action. The company's focused pipeline on first-line mCRC with clear regulatory pathway creates a defined competitive position.

Industry Context

Cardiff Oncology, Inc. operates in Oncology Drugs.

Key facts

Headquarters: San Diego, US

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cardiff Oncology, Inc..

  • The 30 mg onvansertib plus FOLFIRI/bevacizumab combination demonstrated 72.2% confirmed ORR in Phase 2, representing a meaningful efficacy improvement for first-line mCRC patients with RAS mutations.
  • As of June 30, 2026, Cardiff had $34.5 million in cash and believes current resources are sufficient to fund operations into Q3 2027, though Phase 3 advancement depends on additional financing.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2026Completed $10 million registered direct offering to extend cash runway
  • June 2026Presented positive Phase 2 CRDF-004 data at ASCO Annual Meeting showing 72.2% ORR with 30 mg onvansertib plus FOLFIRI/bevacizumab
  • +1 moreTrack every material event for Cardiff Oncology, Inc. as it happens. Explore monitoring →
Get alerted when Cardiff Oncology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BayerMultikinase inhibitor for colorectal cancer→Eli LillyBroad oncology portfolio including colorectal cancer treatments→RocheAnti-angiogenic therapy used in combination for mCRC→

Compare Cardiff Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cardiff Oncology, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Cardiff Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cardiff Oncology, Inc. and its top competitor on Cyborg Score”
“What did Cardiff Oncology, Inc. do this quarter?”
“Is Cardiff Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cardiff Oncology, Inc. do?+
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's lead asset, onvansertib, is in late-stage development for first-line RAS-mutated m...
What is Cardiff Oncology, Inc.'s Cyborg Score?+
Cardiff Oncology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cardiff Oncology, Inc.'s main competitors?+
Named competitors include Bayer, Eli Lilly, Roche. The full competitive landscape is in the AskCyborg report.
How can I get the full Cardiff Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cardiff Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cardiff Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Oncology Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Bayer AG8F. Hoffmann-La Roche AG